Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Paclitaxel in Anaplastic Thyroid Cancer
NCT03085056Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2017
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trametinib in anaplastic thyroid cancer (ATC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression-Free Survival at 6 months. Started Mar 2017; status: active, not recruiting.
02
Drugs
trametinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT03085056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085056.